ExodusPoint Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-297,458
| Closed | -$904K | – | 2110 |
|
|
2024
Q4 | $904K | Buy |
297,458
+172,458
| +138% | +$751K | 0.01% | 975 |
|
|
2024
Q3 | $649K | Sell |
125,000
-316,584
| -72% | -$1.57M | ﹤0.01% | 1106 |
|
|
2024
Q2 | $1.14M | Buy |
+441,584
| New | +$1.51M | 0.01% | 982 |
|
|
2023
Q3 | – | Sell |
-27,345
| Closed | -$692K | – | 2243 |
|
|
2023
Q2 | $692K | Buy |
+27,345
| New | +$852K | 0.01% | 1236 |
|
|
2022
Q3 | – | Sell |
-71,966
| Closed | -$995K | – | 2386 |
|
|
2022
Q2 | $995K | Buy |
+71,966
| New | +$1.11M | 0.01% | 1081 |
|
|
2022
Q1 | – | Sell |
-44,037
| Closed | -$719K | – | 2760 |
|
|
2021
Q4 | $719K | Buy |
44,037
+12,565
| +40% | +$209K | 0.01% | 1237 |
|
|
2021
Q3 | $877K | Sell |
31,472
-778
| -2% | -$22.2K | 0.01% | 1086 |
|
|
2021
Q2 | $956K | Sell |
32,250
-69
| -0.2% | -$1.99K | 0.01% | 1035 |
|
|
2021
Q1 | $903K | Buy |
32,319
+15,812
| +96% | +$437K | 0.01% | 980 |
|
|
2020
Q4 | $468K | Sell |
16,507
-69,152
| -81% | -$1.79M | ﹤0.01% | 1292 |
|
|
2020
Q3 | $2.15M | Buy |
85,659
+36,263
| +73% | +$951K | 0.04% | 380 |
|
|
2020
Q2 | $1.21M | Buy |
+49,396
| New | +$975K | 0.03% | 649 |
|
|
2020
Q1 | – | Sell |
-11,765
| Closed | -$191K | – | 1742 |
|
|
2019
Q4 | $191K | Buy |
+11,765
| New | +$182K | ﹤0.01% | 1348 |
|
Other funds holding RVNC
ExodusPoint Capital Management's RVNC Position: Q1 2025 in Review
ExodusPoint Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 297,458 shares — an estimated $904K sold.
ExodusPoint Capital Management first reported a position in RVNC in Q4 2019 and held it in 13 quarters. The position peaked at $2.15M in Q3 2020. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- ExodusPoint Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- ExodusPoint Capital Management sold 297,458 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $904K.
- ExodusPoint Capital Management first reported a position in Revance Therapeutics, Inc. in Q4 2019 and held it in 13 quarters.
- ExodusPoint Capital Management's Revance Therapeutics, Inc. position peaked at $2.15M in Q3 2020.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on ExodusPoint Capital Management's 13F filing for Q1 2025, filed 14 May 2025.